Clinical Trial

Treatment of Multiple Myeloma

Study Description

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Biological - bb2121

bb2121

Drug - Daratumumab

Daratumumab

Drug - Pomalidomide

Pomalidomide

Drug - Dexamethasone

Dexamethasone

Drug - Bortezomib

Bortezomib

Drug - Ixazomib

Ixazomib

Drug - Lenalidomide

Lenalidomide

Drug - Carfilzomib

Carfilzomib

Drug - Elotuzumab

Elotuzumab

Additional Information

Official Study Title

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Clinical Trial ID

NCT03651128

ParticipAid ID

eVOAWa